Topics

Cancer Immunotherapies That Harness Pre-Existing Antiviral Immunity

20:00 EDT 27 Jun 2019 | NIH

The treatment of cancer using immunotherapies has garnered substantial attention and excitement following clinical benefit observed in patient populations previously refractory to treatment. New approaches continue to be developed to increase the subset of cancer patients responding to treatment – and to address the issue that highly personalized treatments may have manufacturing challenges.  Furthermore, the field is open to new approaches with more promising toxicity profiles. This technology recognizes that the induction of anti-tumor T cell responses is a critical element in the development of effective immunotherapies against cancer.

This novel technology developed by researchers at the National Cancer Institute (NCI) is a cancer immunotherapy that harnesses the potent pre-existing cellular immunity against a commonly acquired virus, human cytomegalovirus (HCMV) that causes well controlled chronic infection in immunocompetent people.  Using tumor tropic human papillomavirus pseudovirions, that contain plasmids expressing HCMV peptides or direct intra-tumoral injection of HCMV peptides, this methodology directs the pre-existing anti-HCMV immunity against those peptides to the tumors.  In the presence of an immune response modifier, such as poly-IC, the anti-HCMV cellular immunity is re-directed to kill the cancerous tumors and induce antigen spreading to tumor-associated antigens. 

The NCI seeks licensing and/or co-development of a cancer immunotherapy based on harnessing the pre-existing immune response to a chronic viral pathogen such as human cytomegalovirus (HCMV) to target solid tumors.

IC: 
NCI
NIH Ref. No.: 
E-167-2017
Advantages: 
  • Does not require the laborious process of clonal T-cell expansion seen with CAR-T cell-based immunotherapies
  • More patients potentially treated in shorter amount of time from diagnosis to treatment
  • Not reliant on the identification of specific tumor-associated antigens, so it can be used as an immunotherapy for many different cancer indications
  • “Off the shelf” capabilities provide easier scale-up manufacturing and cost-of-goods
Applications: 
  • Therapeutic for the treatment of cancer
  • Immunotherapy
Development Status: 

Pre-clinical (in vivo)

Updated On: 
Jun 28, 2019
Date Published: 
Friday, June 28, 2019
Provider Classifications: 
Publications: 
Patent Application: 
62/582,097
PCT/US2018/059384
Licensing Contacts: 
Lead Inventor: 
Inventor IC: 
NCI
NCI
NCI
Inventor Lab URL: 
https://ccr.cancer.gov/Laboratory-of-Cellular-Oncology/john-t-schiller
https://ccr.cancer.gov/Laboratory-of-Cellular-Oncology/douglas-r-lowy
LPM FIrst Name: 
John
LPM Last Name: 
Hewes
Inv Is lead: 
LPM Phone: 
240-276-5515
LPM Suffix: 
Ph.D.
LPM Organization: 
NCI - National Cancer Institute
DTDT Classification: 
Therapeutics
DTDT Description: 
Therapeutics
Pat Filing Date: 
2017-11-06
2018-11-06
Collaboration Sought: 
Yes
Institute or Center: 
Collaboration Opportunity: 

Licensing and research collaboration

E Number Only: 
E-167-2017
Inventor First Name: 
John
Nicolas
Douglas
Inventor Last Name: 
Schiller
Cuburu
Lowy

Original Article: Cancer Immunotherapies That Harness Pre-Existing Antiviral Immunity

NEXT ARTICLE

More From BioPortfolio on "Cancer Immunotherapies That Harness Pre-Existing Antiviral Immunity"

Quick Search

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...